Content
Educational summary
SPRAVATO® (esketamine) is an FDA-approved nasal spray for certain adults with treatment-resistant depression. Public labeling describes use as monotherapy or with an oral antidepressant, under restricted distribution and clinical supervision requirements.
Use this information to prepare questions about treatment-day logistics, monitoring, and whether SPRAVATO® may fit your history and needs.
How delivery is generally described
Public product information describes supervised administration in a certified healthcare setting with monitoring requirements. Exact clinic workflows vary and are explained during clinical evaluation when relevant.
Questions people often discuss with a clinician
Prior treatment history, safety considerations, monitoring expectations, logistics, and alternatives are common topics. A licensed clinician applies labeled indications and clinical judgment to the individual.
Safety and monitoring context
Public labeling and REMS program materials emphasize supervised use and safety monitoring. Your clinical team can explain how those requirements shape a visit.